FI3973982T3 - Koostumus munasarjojen kontrolloituun stimulaatioon - Google Patents

Koostumus munasarjojen kontrolloituun stimulaatioon Download PDF

Info

Publication number
FI3973982T3
FI3973982T3 FIEP21196378.0T FI21196378T FI3973982T3 FI 3973982 T3 FI3973982 T3 FI 3973982T3 FI 21196378 T FI21196378 T FI 21196378T FI 3973982 T3 FI3973982 T3 FI 3973982T3
Authority
FI
Finland
Prior art keywords
patient
composition
amh
body weight
pmol
Prior art date
Application number
FIEP21196378.0T
Other languages
English (en)
Finnish (fi)
Inventor
Saez Joan-Carles Arce
Lisbeth Helmgaard
Bjarke Mirner Klein
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Application granted granted Critical
Publication of FI3973982T3 publication Critical patent/FI3973982T3/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FIEP21196378.0T 2017-09-01 2018-08-31 Koostumus munasarjojen kontrolloituun stimulaatioon FI3973982T3 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17189119 2017-09-01

Publications (1)

Publication Number Publication Date
FI3973982T3 true FI3973982T3 (fi) 2024-09-23

Family

ID=59772482

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP21196378.0T FI3973982T3 (fi) 2017-09-01 2018-08-31 Koostumus munasarjojen kontrolloituun stimulaatioon

Country Status (32)

Country Link
US (2) US11744879B2 (enExample)
EP (3) EP3973982B1 (enExample)
JP (2) JP6856819B2 (enExample)
KR (2) KR20250078595A (enExample)
CN (2) CN120617484A (enExample)
AR (1) AR112541A1 (enExample)
AU (1) AU2018326556B2 (enExample)
BR (1) BR112020003379A2 (enExample)
CA (1) CA3073624A1 (enExample)
CL (1) CL2020000482A1 (enExample)
DK (2) DK3675894T3 (enExample)
EA (1) EA202090480A1 (enExample)
ES (2) ES2904787T3 (enExample)
FI (1) FI3973982T3 (enExample)
HR (2) HRP20211802T1 (enExample)
HU (2) HUE068024T2 (enExample)
IL (1) IL272763B2 (enExample)
JO (1) JOP20200034A1 (enExample)
LT (2) LT3973982T (enExample)
MA (2) MA50034B1 (enExample)
MD (2) MD3973982T2 (enExample)
MX (2) MX2020002235A (enExample)
MY (1) MY200791A (enExample)
PH (1) PH12020500404A1 (enExample)
PL (2) PL3973982T3 (enExample)
PT (2) PT3675894T (enExample)
RS (2) RS62810B1 (enExample)
SG (1) SG11202003840QA (enExample)
SI (2) SI3973982T1 (enExample)
TW (1) TWI749255B (enExample)
UA (1) UA126869C2 (enExample)
WO (1) WO2019043143A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
TW202237173A (zh) * 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE267608T1 (de) * 2000-01-27 2004-06-15 Applied Research Systems Verwendung von fsh zur behandlung von infertilität
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
CA2700335C (en) * 2007-09-21 2015-12-01 Pharmabrand S.A. Composition comprising mucilaginous polysaccharides derived from aloe barbadensis combined with liposomes, method for obtaining same and use thereof as a sun protector, an anti-acne agent, an epidermal regenerator and a moisturiser
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
WO2011089602A2 (en) * 2010-01-21 2011-07-28 Ramot At Tel-Aviv University Ltd. Aloe-emodin derivatives and use thereof for the treatment of cancer
RS54214B2 (sr) 2010-09-29 2024-02-29 Ferring Bv Smeša za upotrebu u lečenju infertiliteta
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
CA2945883A1 (en) * 2014-04-18 2015-10-22 Glycotope Gmbh Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone
MD3261661T2 (ro) 2015-02-26 2024-04-30 Ferring Bv Menotropină pentru tratarea infertilității
HUE048757T2 (hu) * 2015-04-17 2020-08-28 Ferring Bv FSH meddõség kezelésére
EP3286209B1 (en) 2015-04-24 2020-11-25 Ferring BV Method of production of gonadotrophin
AU2016282916B2 (en) 2015-06-26 2022-01-20 Ferring B.V. Methods of purification and/or viral inactivation
PL3787667T3 (pl) 2018-04-30 2025-07-28 Ferring B.V. Kompozycja do kontrolowanej stymulacji jajników
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法

Also Published As

Publication number Publication date
US20240024424A1 (en) 2024-01-25
IL272763B2 (en) 2024-02-01
CN111050787A (zh) 2020-04-21
PL3973982T3 (pl) 2024-11-04
AR112541A1 (es) 2019-11-06
EA202090480A1 (ru) 2020-07-20
IL272763B1 (en) 2023-10-01
EP4427806A2 (en) 2024-09-11
SG11202003840QA (en) 2020-05-28
RS65945B1 (sr) 2024-10-31
UA126869C2 (uk) 2023-02-15
CN120617484A (zh) 2025-09-12
JP2021046398A (ja) 2021-03-25
KR20250078595A (ko) 2025-06-02
HRP20211802T1 (hr) 2022-03-04
HUE056726T2 (hu) 2022-03-28
DK3973982T3 (da) 2024-09-23
HUE068024T2 (hu) 2024-12-28
SI3973982T1 (sl) 2024-10-30
MA56224B1 (fr) 2024-09-30
MX2024009224A (es) 2024-08-06
PT3675894T (pt) 2022-01-25
MA50034B1 (fr) 2022-02-28
PT3973982T (pt) 2024-09-16
MA50034A (fr) 2021-05-12
LT3973982T (lt) 2024-09-10
BR112020003379A2 (pt) 2020-08-25
SI3675894T1 (sl) 2022-01-31
EP4427806A3 (en) 2024-10-09
IL272763A (en) 2020-04-30
ES2989511T3 (es) 2024-11-26
TWI749255B (zh) 2021-12-11
CL2020000482A1 (es) 2020-06-26
LT3675894T (lt) 2021-12-10
PL3675894T3 (pl) 2022-02-21
EP3973982A1 (en) 2022-03-30
US20200197493A1 (en) 2020-06-25
US11744879B2 (en) 2023-09-05
EP3973982B1 (en) 2024-07-31
WO2019043143A1 (en) 2019-03-07
MY200791A (en) 2024-01-16
JP2020528071A (ja) 2020-09-17
MD3973982T2 (ro) 2024-11-30
AU2018326556A1 (en) 2020-03-05
MX2020002235A (es) 2020-07-20
AU2018326556B2 (en) 2024-09-26
TW201919687A (zh) 2019-06-01
PH12020500404A1 (en) 2021-03-01
MA56224A (fr) 2022-04-20
JP7373479B2 (ja) 2023-11-02
ES2904787T3 (es) 2022-04-06
KR20200045543A (ko) 2020-05-04
EP3675894B1 (en) 2021-11-03
EP3675894A1 (en) 2020-07-08
MD3675894T2 (ro) 2022-03-31
CA3073624A1 (en) 2019-03-07
JOP20200034A1 (ar) 2020-02-13
HRP20241171T1 (hr) 2024-11-22
DK3675894T3 (da) 2022-01-24
RS62810B1 (sr) 2022-02-28
JP6856819B2 (ja) 2021-04-14

Similar Documents

Publication Publication Date Title
RU2739037C3 (ru) Композиция для контролируемой стимуляции яичников
PH12018501424B1 (en) A composition for treating diabetes or diabesity comprising oxyntomodulin analog
RU2017128296A (ru) Композиция для лечения бесплодия
RU2017123880A (ru) Антагонисты миостатина или активина для лечения саркопении
MX2017008569A (es) Derivados de glucagon con estabilidad mejorada.
FI3229828T3 (fi) Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio
FI3973982T3 (fi) Koostumus munasarjojen kontrolloituun stimulaatioon
Hamilton et al. The potential impact of GLP‐1 agonists on obstructive sleep apnoea.
TN2015000480A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
FI3648788T3 (fi) Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää
JP2021046398A5 (enExample)
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
Hwang et al. A novel very long-acting insulin analog (HM12470) with potential for once-weekly dosing, has a favorable PK, PD and mitogenic profile
TH2001001168A (th) องค์ประกอบสำหรับการกระตุ้นรังไข่แบบควบคุม
RU2017140515A (ru) Способ лечения рассеянного склероза (варианты)
CA3069256A1 (en) Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf
RU2020137769A (ru) Композиция для контролируемой стимуляции яичников
Amin et al. C30 new insights in pathogenesis of sleep disordered breathing: treatment of obstructive sleep apnea with glucagon like peptide-1 receptor agonist
Enck et al. Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo
NZ761634B2 (en) Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine
NZ761634A (en) Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine
RU2613187C1 (ru) Способ лечения гиперкинетического синдрома у пациентов в вегетативном состоянии и состоянии малого сознания
Masoodi et al. possibility of coincidental occurrence of the two tumors cannot be ignored.
TW202547550A (zh) 司馬魯肽在醫學上的用途
Masoodi et al. Growth hormone secreting pituitary macroadenoma and meningioma: An association or coincidence?